Navigation Links
PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
Date:7/27/2009

tt R. Plotkin, M.D., Ph.D., director of the Neurofibromatosis Clinic at the Pappas Center for Neuro-Oncology in the Massachusetts General Hospital Cancer Center. "If shown to be efficacious, we believe that its oral administration and generally well-tolerated profile could make PTC299 an especially appealing treatment approach for NF2 patients with growing vestibular schwannomas."

The new PTC299 clinical study is an open-label Phase 2 trial that will evaluate the efficacy, safety, and pharmacodynamics of PTC299 in up to 25 patients with NF2 for up to 48 weeks. The primary objective of the study is to assess how PTC299 affects tumor volume and changes in hearing and word recognition among patients with NF2. The trial will also assess the effects of PTC299 on tumor blood flow and VEGF-related proteins. The study will be conducted at the Massachusetts General Hospital in Boston, Massachusetts.

"We are excited to rapidly advance the clinical development of PTC299 in NF2," said Langdon Miller, M.D., Chief Medical Officer of PTC Therapeutics. "We are hopeful that the novel mechanism of PTC299 will address unmet medical need for patients with NF2, building upon ongoing evaluations of the drug in patients with metastatic breast cancer, Kaposi's sarcoma, and other solid tumors."

In previous Phase 1 clinical studies, PTC299 was generally well tolerated by healthy volunteers who received single or multiple doses, with no serious, dose-limiting or definitively drug-related adverse events reported. All clinical adverse events observed were mild or moderate in severity, did not require intervention, and were not clearly related to PTC299. In addition, adverse events such as bleeding, hypertension and proteinuria were not observed.

The Phase 2 clinical trial of PTC299 is supported by a grant from the U.S. Department of Defense Neurofibromatosis Research Program.

About PTC299
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
2. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
3. Cell Therapeutics, Inc. Announces Exercise of Overallotment
4. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
5. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
7. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
8. Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens
9. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
10. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
11. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Women in the ... to an additional family planning option. Sayana® Press ... at all levels of the health system and ... a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with ... is the first of four African countries expected ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Unraveling life’s ... together. The Archer Family purchased a DNA ... DNA, but ended up with a lifetime of memories, ... within the family members’ DNA genuinely brought the family ... to search deeper into genetic history and prior to ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
(Date:7/10/2014)... 2014   Ceres, Inc . (Nasdaq: ... today financial results for the three months ended May ... Ceres reported that the company and its ... growing season in Brazil, which concluded in June, despite ... evaluation areas for part of the growing season. Yields ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... Submission demonstrates progress of plant-derived insulin program, ... -, TSX symbol: SBS, CALGARY, July ... company developing a portfolio of therapeutic,proteins for metabolic ... an Investigational New Drug (IND) application for,safflower-produced recombinant ...
... ArunA Biomedical, Inc., the first,company to commercialize human ... that William T. Sharp has been named President,and ... leadership,responsibilities, Mr. Sharp has also been appointed to ... Steven Stice, PhD, who will,remain ArunA,s Chairman and ...
... MADISON Though bacteria are everywhere from the air we ... the vast majority are innocuous or even beneficial, and only ... microbial guest from an unwanted intruder? , Research from the ... but with the host. , A study appearing online this week ...
Cached Biology Technology:SemBioSys submits IND for safflower-produced insulin to U.S. FDA 2SemBioSys submits IND for safflower-produced insulin to U.S. FDA 3ArunA Biomedical Names William T. Sharp President and Chief Executive Officer 2Symbiotic microbes induce profound genetic changes in their hosts 2
(Date:7/11/2014)... City of Entiat on Tuesday, July 8, 2014. Despite ... to over 1,000 acres by evening. Three outbuildings were ... by the Washington Department of Natural Resources. The ... developing fire control strategies and tactics. Other cooperators include ... Natural Resources, (WA DNR), Bureau of Land Management, Chelan ...
(Date:7/11/2014)... the National Institute of Standards and Technology (NIST) ... more effectively, they often prove that necessity is ... case recently for M. Lorna De Leoz and ... specialization of glycomics. Glycomics is the study of ... are attached to proteins and lipids and influence ...
(Date:7/11/2014)... have explored two different ways that allow unprecedented ... the formation of oxygen molecules in photosynthesis. The ... journal Nature Communications . , "The new ... for water oxidation, which are key components for ... of solar energy in fuels like hydrogen, ethanol ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... IODP Arctic Coring Expedition (ACEX) is making news with new ... Nature, an article by several of the expedition scientists summarizes ... unusually wet, and ice-free up to the time the last ... atmosphere ?a period calculated to have occurred 55 million years ...
... designated Special Areas of Conservation throughout the UK, including ... pile driving. The frequency range of pile driving noise ... and avoid predators. This has the potential to affect ... Lactating females and young calves might be particularly vulnerable ...
... studies offer new evidence suggesting an alternative form of natural ... the blood in humans at levels determined to protect against ... in eight different forms. The primary vitamin E on drugstore ... of vitamin E surfacing as a potent neuroprotective agent in ...
Cached Biology News:Arctic coring expedition continues to yield new clues 2Dolphins at risk 2Natural vitamin E tocotrienol reaches blood at protective levels 2Natural vitamin E tocotrienol reaches blood at protective levels 3
...
... Arrays can be used to test the ... and sera that are commonly used as ... contains spots for 21 different protein preparations ... antibody crossreactivity and species specificity, QC of ...
... DNA sequencing is the experimental process ... DNA region. The automated DNA Sequencing is ... thermostable DNA polymerase, which allows cycle sequencing ... and detected in a capillary instrument controlled ...
... On-Demand Cytometry The Guava ... blue laser based multiparameter cytometer with built-in ... you can screen plates of cells and ... of manipulating multiple tubes or having the ...
Biology Products: